TY - JOUR
T1 - Systematic functional testing of rare variants
T2 - Contributions of CFI to age-related macular degeneration
AU - Tan, Perciliz L.
AU - Garrett, Melanie E.
AU - Willer, Jason R.
AU - Campochiaro, Peter A.
AU - Campochiaro, Betsy
AU - Zack, Donald J.
AU - Ashley-Koch, Allison E.
AU - Katsanis, Nicholas
N1 - Funding Information:
The authors thank the AMD patients and their families for their participation in this study and the scientists at the Center for Human Disease Modeling for their helpful comments and edits. They also thank Ali Torkamani and his group for sharing data on the Wellderly cohort. Supported by grants from NIH (5T32EY007143, 5P30EY001765), Foundation Fighting Blindness, Edward N. & Della L. Thome Memorial Foundation Awards Program in Age-Related Macular Degeneration Research, unrestricted funds from Research to Prevent Blindness, Inc., and generous gifts from the Guerrieri Family Foundation; funding supported the collection of samples.
Publisher Copyright:
© 2017 The Authors.
PY - 2017/3
Y1 - 2017/3
N2 - Purpose. Genome-wide association (GWAS) and sequencing studies for AMD have highlighted the importance of coding variants at loci that encode components of the complement pathway. However, assessing the contribution of such alleles to AMD, especially when they are rare, remains coarse, in part because of the persistent challenge in establishing their functional relevance. Others and we have shown previously that rare alleles in complement factor I (CFI) can be tested functionally using a surrogate in vivo assay of retinal vascularization in zebrafish embryos. Here, we have implemented and scaled these tools to assess the overall contribution of rare alleles in CFI to AMD. Methods. We performed targeted sequencing of CFI in 731 AMD patients, followed by replication in a second patient cohort of 511 older healthy individuals. Systematic functional testing of all alleles and post-hoc statistical analysis of functional variants was also performed. Results. We discovered 20 rare coding nonsynonymous variants, including the previously reported G119R allele. In vivo testing led to the identification of nine variants that alter CFI; six of which are associated with hypoactive complement factor I (FI). Post-hoc analysis in ethnically matched, population controls showed six of these to be present exclusively in cases. Conclusions. Taken together, our data argue that multiple rare and ultra-rare alleles in CFI contribute to AMD pathogenesis; they improve the precision of the assessment of the contribution of CFI to AMD; and they offer a rational route to establishing both causality and direction of allele effect for genes associated with this disorder.
AB - Purpose. Genome-wide association (GWAS) and sequencing studies for AMD have highlighted the importance of coding variants at loci that encode components of the complement pathway. However, assessing the contribution of such alleles to AMD, especially when they are rare, remains coarse, in part because of the persistent challenge in establishing their functional relevance. Others and we have shown previously that rare alleles in complement factor I (CFI) can be tested functionally using a surrogate in vivo assay of retinal vascularization in zebrafish embryos. Here, we have implemented and scaled these tools to assess the overall contribution of rare alleles in CFI to AMD. Methods. We performed targeted sequencing of CFI in 731 AMD patients, followed by replication in a second patient cohort of 511 older healthy individuals. Systematic functional testing of all alleles and post-hoc statistical analysis of functional variants was also performed. Results. We discovered 20 rare coding nonsynonymous variants, including the previously reported G119R allele. In vivo testing led to the identification of nine variants that alter CFI; six of which are associated with hypoactive complement factor I (FI). Post-hoc analysis in ethnically matched, population controls showed six of these to be present exclusively in cases. Conclusions. Taken together, our data argue that multiple rare and ultra-rare alleles in CFI contribute to AMD pathogenesis; they improve the precision of the assessment of the contribution of CFI to AMD; and they offer a rational route to establishing both causality and direction of allele effect for genes associated with this disorder.
KW - Complement pathway
KW - In vivo testing
KW - Rare allele burden
UR - http://www.scopus.com/inward/record.url?scp=85015260830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015260830&partnerID=8YFLogxK
U2 - 10.1167/iovs.16-20867
DO - 10.1167/iovs.16-20867
M3 - Article
C2 - 28282489
AN - SCOPUS:85015260830
SN - 0146-0404
VL - 58
SP - 1570
EP - 1576
JO - Investigative Ophthalmology and Visual Science
JF - Investigative Ophthalmology and Visual Science
IS - 3
ER -